Lilly battles five-year flu: Analysts: Drugmaker primed for rebound from Prozac defeat

It's been a challenging five years for Eli Lilly and Co., which has launched nine new drugs yet seen the price of its stock fall by half, wiping out more than $60 billion in market value. However, company officials say the drugmaker has rallied from the jarring setback it received Aug. 9, 2000-when a federal appeals court invalidated Prozac's patent protection-and are optimistic better times lie ahead. They say the company is positioned to increase profit and revenue, thanks to...

 

You have accessed IBJ.com Premium online content

IBJ.com Premium online content is identified by locked premium or unlocked premium symbol to the right of the headline. Access to all IBj.com Premium online content requires a paid IBJ.com Premium subscription and the subscriber to be logged in using their email and password. See subscription options below.

Log In if you are a subscriber to IBJ.com Premium Online

...Or choose the IBJ subscription that's right for you:

7 Day Subscription

$4.95 per week

IBJ.com
Premium online

Order Now
   

1 Year Subscription

$1.25 per week

IBJ.com
Premium online

Order Now
 

1 Year Subscription

$1.52 per week

IBJ Print
only

Order Now

 

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
ADVERTISEMENT